EGFR and non-small cell lung carcinoma: A precision medicine approach has been successfully applied in medical oncology for the treatment of non-small-cell lung cancer (NSCLC) through the identification of targetable driver molecular aberrations; activating mutations of epidermal growth factor receptor (EGFR) are the most common (10%-15% of Caucasian and 30%-40% of Asian patients with non-squamous histotype).1